Beryl Drugs Reports Mixed Financial Results, Highlights Profit Growth Amid Challenges in August 2025
Beryl Drugs has announced its financial results for the quarter ending June 2025, showing a flat performance. The company reported a profit after tax of Rs 0.17 crore, an improvement from the previous year. However, profit before tax has declined to its lowest level in five quarters, indicating ongoing challenges.
Beryl Drugs, a microcap company in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending June 2025. The results, declared on August 7, 2025, indicate a flat financial performance for the period. Notably, the company's evaluation has undergone an adjustment, with its score rising to 1 from 0 over the past three months.In terms of positive developments, Beryl Drugs has reported a profit after tax (PAT) of Rs 0.17 crore for the latest six-month period, which surpasses the PAT of Rs 0.08 crore recorded in the preceding twelve months. This achievement highlights the company's ability to exceed its previous performance within a shorter timeframe.
Conversely, the financial results also reveal challenges for Beryl Drugs. The profit before tax (PBT), excluding other income, has reached its lowest point in the last five quarters at Rs 0.07 crore. This trend suggests a negative trajectory in the near term for PBT.
Overall, Beryl Drugs' recent financial results reflect a mix of progress and challenges, leading to a revision in its score.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
